Biomarker Menu
Biomarker Menu

Explore Our Biomarker Menu

Including 400+ Biomarker Offerings for a Range of Disease States

Return to Biomarker Menu

Biomarker: MDM2 (self-ubiquitinated)

Search for Biomarkers

Analyte:

MDM2 (self-ubiquitinated)

Platform:

Status:

Experienced Running

Biological or Clinical Significance:

Like many E3 ligases, MDM2 undergoes autoubiquitylation. Although it was originally thought that MDM2 autoubiquitylation promotes autodegradation, it has recently been shown that this may not be the case, but rather, autoubiquitylation may actually activate the E3 ligase activity of MDM2, and promote p53 targeting. This is proposed to occur through recruitment of E3 conjugating enzyme to the poly-ubiquitin chain on MDM2. Mdm2 that has been conjugated to polyubiqui-tin chains, but not to single ubiquitins, exhibits substantially enhanced activity to polyubiquitinate p53. Echanistically, auto-ubiquitination of Mdm2 facilitates the recruitment of the E2 ubiquitin-conjugating enzyme. Mutations that diminish the noncovalent interactions render auto-ubiquitination unable to stimulate Mdm2 substrate E3 activity. The specificity and efficiency of ubiquitination are largely determined by the E3, which binds to both an E2 thio-esterified with ubiquitin (E2Ub) and a substrate protein, and stimulates the transfer of ubiquitin from E2Ub to the sub-strate.

References:

Speak to a Scientist

















What would you like to discuss?

With whom will we be speaking?






I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.

Yes I confirm that I am over the age of 16 and I consent to communications from BioAgilytix.


biomarker services

Services

See how our premier bioanalytical services support all phases of biomarker, immunogenicity, PK, and cell-based assay studies.

Explore our services

case studies

Case Studies

Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.

Read our case studies